Patents by Inventor JOHN BUELL

JOHN BUELL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    Publication number: 20240025923
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: July 3, 2023
    Publication date: January 25, 2024
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell
  • BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    Publication number: 20240018162
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 18, 2024
    Inventors: John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
  • Compounds and methods for CD73 modulation and indications therefor
    Patent number: 11807626
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 7, 2023
    Assignee: Opna Bio SA
    Inventors: Songyuan Shi, John Buell, Zuojun Guo, Cuong Ly, Wayne Spevak, Mark Vander Wal, Jack Walleshauser, Chao Zhang, Jiazhong Zhang
  • Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
    Patent number: 11739101
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: August 29, 2023
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell
  • COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR
    Publication number: 20230081426
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: R1, R2, R3, X, and Z are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: September 20, 2021
    Publication date: March 16, 2023
    Inventors: Jiazhong Zhang, John Buell, Phuongly Pham, Wayne Spevak, Mark Vander Wal, Xinping Han, Chao Zhang, Zuojun Guo, Jack Walleshauser, Ying Zhang, Steven Rank, Yasuyuki Ogawa, Songyuan Shi
  • Compounds and methods for EP300 or CBP modulation and indications therefor
    Patent number: 11446287
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: September 20, 2022
    Assignee: Opna Immuno-Oncology SA
    Inventors: Wayne Spevak, John Buell, Zuojun Guo, Hiroaki Inagaki, Yongil Jin, Phuongly Pham, Songyuan Shi, Jack Walleshauser, Jeffrey Wu, Guoxian Wu, Chao Zhang, Jiazhong Zhang, Ying Zhang
  • COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR
    Publication number: 20220144805
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.
    Type: Application
    Filed: April 22, 2021
    Publication date: May 12, 2022
    Inventors: Songyuan Shi, John Buell, Zuojun Guo, Cuong Ly, Wayne Spevak, Mark Vander Wal, Jack Walleshauser, Chao Zhang, Jiazhong Zhang
  • BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    Publication number: 20210355140
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 18, 2021
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell
  • Compounds and methods for IDO and TDO modulation, and indications therefor
    Patent number: 11149011
    Abstract: Disclosed are compounds of Formula (I) and (Ia): or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R4, R5, R6, and R7 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: October 19, 2021
    Assignee: Plexxikon Inc.
    Inventors: Jiazhong Zhang, Hannah Powers, Aaron Albers, Phuongly Pham, Guoxian Wu, John Buell, Wayne Spevak, Zuojun Guo, Jack Walleshauser, Ying Zhang
  • COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR
    Publication number: 20210315872
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 14, 2021
    Inventors: Wayne Spevak, John Buell, Zuojun Guo, Hiroaki Inagaki, Yongil Jin, Phuongly Pham, Songyuan Shi, Jack Walleshauser, Jeffrey Wu, Guoxian Wu, Chao Zhang, Jiazhong Zhang, Ying Zhang
  • COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR
    Publication number: 20210198239
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 1, 2021
    Inventors: Mark Vander Wal, John Buell, Xinping Han, Yongil Jin, Guoxian Wu, Songyuan Shi, Wayne Spevak, Jack Walleshauser, Jiazhong Zhang, Ying Zhang, Zuojun Guo
  • Compounds and methods for CDK8 modulation and indications therefor
    Patent number: 10703757
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, X3, X4, X5, X6, X7 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 7, 2020
    Assignee: Plexxikon Inc.
    Inventors: Guoxian Wu, Aaron Albers, John Buell, Elizabeth A. Burton, Phuongly Pham, Hannah Powers, Songyuan Shi, Wayne Spevak, Jeffrey Wu, Jiazhong Zhang
  • Heterocyclic compounds and uses thereof
    Patent number: 10519177
    Abstract: Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: December 31, 2019
    Assignee: Plexxikon Inc.
    Inventors: Jiazhong Zhang, John Buell, Katrina Chan, Prabha N. Ibrahim, Jack Lin, Phuongly Pham, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jeffrey Wu
  • Compounds and methods for IDO and TDO modulation, and indications therefor
    Patent number: 10508085
    Abstract: Disclosed are compounds of Formula I(a): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 17, 2019
    Assignee: Plexxikon Inc.
    Inventors: Jiazhong Zhang, Hannah Powers, Aaron Albers, Phuongly Pham, Guoxian Wu, John Buell, Wayne Spevak, Zuojun Guo, Jack Walleshauser, Ying Zhang
  • COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR
    Publication number: 20190300487
    Abstract: Disclosed are compounds of Formula (I) and (Ia): or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R4, R5, R6, and R7 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: March 19, 2019
    Publication date: October 3, 2019
    Inventors: Jiazhong Zhang, Hannah Powers, Aaron Albers, Phuongly Pham, Guoxian Wu, John Buell, Wayne Spevak, Zuojun Guo, Jack Walleshauser, Ying Zhang
  • Compounds and methods for kinase modulation, and indications therefor
    Patent number: 10227357
    Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: March 12, 2019
    Assignee: Plexxikon Inc.
    Inventors: Jack Lin, John Buell, Katrina Chan, Todd Ewing, Prabha Ibrahim, Marika Nespi, Phuongly Pham, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jiazhong Zhang, Ying Zhang
  • Compounds and methods for kinase modulation, and indications therefor
    Patent number: 10160747
    Abstract: Disclosed are compounds of Formula I(b): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R3, R4, R5, each R7, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: December 25, 2018
    Assignee: Plexxikon Inc.
    Inventors: Jack Lin, Prabha N. Ibrahim, Aaron Albers, John Buell, Zuojun Guo, Phuongly Pham, Hannah Powers, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jiazhong Zhang, Ying Zhang, Jeffrey Wu
  • Compounds and methods for kinase modulation, and indications therefor
    Patent number: 10160755
    Abstract: Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R1, R2, Q1, Q2, and Q3, are described in this disclosure, compositions thereof, and methods and uses thereof.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: December 25, 2018
    Assignee: Plexxikon Inc.
    Inventors: Jack Lin, Phuongly Pham, John Buell, Ken Dong, Prabha Ibrahim, Wayne Spevak, Garson Tsang, Guoxian Wu, Ying Zhang
  • COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR
    Publication number: 20180215763
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, X3, X4, X5, X6, X7 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 2, 2018
    Inventors: Guoxian Wu, Aaron Albers, John Buell, Elizabeth A. Burton, Phuongly Pham, Hannah Powers, Songyuan Shi, Wayne Spevak, Jeffrey Wu, Jiazhong Zhang
  • COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR
    Publication number: 20180099939
    Abstract: Disclosed are compounds of Formula I(a): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 12, 2018
    Inventors: Jiazhong Zhang, Hannah Powers, Aaron Albers, Phuongly Pham, Guoxian Wu, John Buell, Wayne Spevak